Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427881 | 0.82 | RXFP1 (0.48) | POLBBRD4ALDH1A1KDM4E | |
| SCHEMBL426957 | 0.77 | PSEN1 (0.47) | ALDH1A1KAT6A | |
| SCHEMBL1767675 | 0.77 | CA1 (0.53) | POLBCCR2KCNH2PIK3CBAKR1B1 | |
| SCHEMBL2371261 | 0.77 | POLB (0.50) | POLBCCR2KCNH2PIK3CBAKR1B1 | |
| SCHEMBL2371266 | 0.77 | CCR2 (0.53) | POLBCCR2KCNH2PIK3CBAKR1B1 | |
| SCHEMBL30902183 | 0.77 | POLB (0.50) | POLBCCR2KCNH2PIK3CBAKR1B1 | |
| SCHEMBL24429412 | 0.74 | CCR2 (0.50) | POLBCCR2KCNH2PIK3CBAHR | |
| SCHEMBL429956 | 0.74 | POLB (0.48) | POLBCCR2KCNH2PIK3CBAKR1B1 | |
| SCHEMBL778076 | 0.73 | AKR1B1 (0.58) | POLBCCR2KCNH2PIK3CBAKR1B1 | |
| SCHEMBL7591202 | 0.73 | CCR2 (0.60) | POLBCCR2KCNH2PIK3CDBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835461-B2 | Substituted 3-hydroxy-4-pyridone derivative | SHIONOGI & CO., LTD. (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2412708-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | Shionogi&Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022255-A1 | SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE | ENDOD1, CNBP, DPP4 | POLB 368/4885CCR2 4157/4885KCNH2 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.